Ironwood Pharmaceuticals Q4 FY2022 Investor Update

Loading viewer...

earnings

Format: PDF earnings

Ironwood Pharmaceuticals Q4 and full-year 2022 investor update presented February 16, 2023, covering financial results, LINZESS commercial performance, and pipeline progress including linaclotide pediatric indications, CNP-104 for PBC, and IW-3300 development programs.

Browse all earningss →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Ironwood Pharmaceuticals

View all →

FloQast_Ironwood%20Pharmaceuticals%20Case%20Study_2021

brochure

presentation

Similar earningss from other companies

Browse all →

Interim Results August 2023 | H1 Financial Performance

earnings

46 Pages

ΤΙΤΑΝ

Action Construction Equipment Q4 FY23 Earnings Presentation

earnings